The Proteomics Frontier Webinar Series:
Decoding Complex Inflammatory Diseases with
Affinity Proteomics
June 24, 2025 | 7:00 AM PST, 10:00 AM EST, 4:00 PM CEST, 3:00 PM BST | Zoom Webinar
Olink® Proteomics enables the discovery of biomarkers with unparalleled specificity and sensitivity. Olink’s platform has been widely adopted due to its scalability and actionability to help answer research questions aiming to elucidate signaling pathways immunological diseases, novel mechanisms of drug action, or as a tool to identify actionable biomarker signatures with a prognostic/predictive value.
This webinar will review how the technology has been applied to the study of a wide variety of common complex inflammatory diseases. Particularly in the study of pathologies at mucosal interfaces like the lung and the gut, thereby improving our understanding of microbiome-induced changes of the host’s immune system and its systemic pathological consequences.
We will explore several case studies demonstrating the development of biomarker signatures for clinical screening, disease progression monitoring, and informed clinical decision-making—ultimately driving advancements in healthcare and enhancing quality of life.We will review several case studies related to the development of biomarker signatures for clinical screening and for disease progression and to support clinical decision making to ultimately improve the quality of life and improve health.
Key Learnings:
- Describe the use of affinity-based proteomics in studying a wide variety of common complex inflammatory diseases and pathologies at mucosal interfaces.
- Understand microbiome-induced changes of the host’s immune system and its systemic pathological consequences.
- Define how to identify actionable biomarkers underscoring the role of precision proteomics as a tool to improve health outcomes for patients with autoimmune and autoinflammatory diseases
Who should attend:
- Senior Scientist/Principal Scientist/Principal Investigator
- Biomarker Scientist/Assay Scientist/Translational Scientist/Protein Scientist
- R&D Lead/Clinical Biomarker Lead
- Post-Doctoral Researcher/Research Fellow
- Researcher/Senior Research Associate
- Associate/Full Professor
- Professionals in pharma/biotech companies
- Contract research organizations
Speaker:
Michael Förster completed his PhD on autoimmune disease genetics at Karolinska Institute and moved to McGill University for a postdoc investigating the link between primary immunodeficiency, hematopoiesis, and the development of hematological malignancies. He left academia for a stint at the Fraunhofer Society to manage projects in liquid biopsy based cancer diagnostics and CAR T cell therapy and more recently worked for Azenta Life Sciences as Scientific Liaison for biospecimen procurement and genomics services.